It is important to note that, while our preclinical work focused entirely on anti-PD1, our clinical cohort is mixed—comprising patients with metastatic NSCLC and melanoma (n = 109) treated with either ICI monotherapy (anti-PD1, anti-CLTA4, or anti-PDL1) or ICIs in combination with other treatment modalities (e.g., chemotherapy). The gene discussed is CD274; the disease is melanoma.